The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“…al, 1992; Di Marzo et al, 1994) is the first characterized exampleFand their attending CB1 cannabinoid receptors, which are expressed in brain areas involved in the control of motor functions, cognition, and motivation (Herkenham et al, 1990; Matsuda et al, 1993; Glass et al, 1997; Piomelli 2003).”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Self-citationFormation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationCannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts
Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92620-1 · Cited by 1,166
Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodríguez de Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., et al. (2003) · Nature · doi:10.1038/nature01921 · Cited by 1,064
Self-citationControl of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Self-citationGlass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Self-citationAn anorexic lipid mediator regulated by feeding
Rodríguez de Fonseca, F., Navarro, M., Gómez, R., Escuredo, L., Nava, F., Fu, J., Murillo-Rodríguez, E., Giuffrida, A., LoVerme, J., Gaetani, S., et al. (2001) · Nature · doi:10.1038/35102582 · Cited by 694
Self-citationThe Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders
Linszen, D. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040017002 · Cited by 656
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652
Localization of cannabinoid receptor mRNA in rat brain
Matsuda, L. A., Bonner, T. I., & Lolait, S. J. (1993) · Journal of Comparative Neurology · doi:10.1002/cne.903270406 · Cited by 631 · cited 1×
“…al, 1992; Di Marzo et al, 1994) is the first characterized exampleFand their attending CB1 cannabinoid receptors, which are expressed in brain areas involved in the control of motor functions, cognition, and motivation (Herkenham et al, 1990; Matsuda et al, 1993; Glass et al, 1997; Piomelli 2003).”
BackgroundHorrobin, D. F. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00151-5 · Cited by 455
Elevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00008 · Cited by 432
Self-citationDean, B., Sundram, S., Bradbury, R., Scarr, E., & Copolov, D. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00552-2 · Cited by 383
Endocannabinoid signalling in the blood of patients with schizophrenia.
Marchi, N. D., PETROCELLIS, L. D., Orlando, P., Daniele, F., Fezza, F., & Marzo, V. D. (2003) · Lipids in Health and Disease · doi:10.1186/1476-511x-2-5 · Cited by 275
Reversal of Dopamine D2Receptor Responses by an Anandamide Transport Inhibitor
Beltramo, M., de Fonseca, F. R., Navarro, M., Calignano, A., Gorriti, M. A., Grammatikopoulos, G., Sadile, A. G., Giuffrida, A., & Piomelli, D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03401.2000 · Cited by 232
Self-citationCNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
Ujike, H., Takaki, M., Nakata, K., Tanaka, Y., Takeda, T., Kodama, M., Fujiwara, Y., Sakai, A., & Kuroda, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001029 · Cited by 228
Emrich, H. M., Leweke, F. M., & Schneider, U. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00426-1 · Cited by 226
Self-citationAndréasson, S., Allebeck, P., Engström, A., & Rydberg, U. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91823-5 · Cited by 202
Substance Use Disorder and the Early Course of Illness in Schizophrenia and Affective Psychosis
Kovasznay, B., Fleischer, J., Tanenberg-Karant, M., Jandorf, L., Miller, A. D., & Bromet, E. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.2.195 · Cited by 177
Cannabis induced dopamine release: an in-vivo SPECT study
Voruganti, L. N. P., Slomka, P., Zabel, P., Mattar, A., & Awad, A. G. (2001) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(01)00104-4 · Cited by 172
Quantification of Bioactive Acylethanolamides in Rat Plasma by Electrospray Mass Spectrometry
Giuffrida, A., Rodríguez de Fonseca, F., & Piomelli, D. (2000) · Analytical Biochemistry · doi:10.1006/abio.2000.4509 · Cited by 164
Self-citationFerrer, B., Asbrock, N., Kathuria, S., Piomelli, D., & Giuffrida, A. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02896.x · Cited by 156
Self-citationGorriti, M. Á., de Fonseca, F. R., Navarro, M., & Palomo, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00851-6 · Cited by 137
Sim‐Selley, L. J., & Martin, B. R. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035618 · Cited by 125
Leweke, F. M., Schneider, U., Thies, M., Münte, T. F., & Emrich, H. M. (1999) · Psychopharmacology · doi:10.1007/s002130050884 · Cited by 102 · cited 3×
“…signaling may be associated with schizophrenia is further supported by studies showing that endocannabinoid levels in cerebrospinal fluid (CSF) (Leweke et al, 1999b) and plasma (Yao et al, 2002; De Marchi et al, 2003) as well as CB1 receptor expression (Dean et al, 2001) are abnormal in…”
BackgroundResultSelf-citationReduced binocular depth inversion in regular cannabis users
Semple, D. M., Ramsden, F., & McIntosh, A. M. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00140-0 · Cited by 78
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
An Introduction to the Endogenous Cannabinoid System
Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
“First, in a relatively large cohort of antipsychotic-naı̈ve schizophrenic patients (n1⁄4 47), cerebrospinal anandamide levels were found to be inversely correlated with psychotic symptoms.(13) Second, highrisk subjects for psychosis(35) who exhibited lower cerebrospinal”
BackgroundSelf-citationTargeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Metadata
- Authors
- Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J., & Piomelli, D.
- Venue
- Neuropsychopharmacology
- Published
- 2004-09-08
- Volume
- 29
- Issue
- 11
- Pages
- 2108-2114
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2096003899
- Cited by
- 480
- References
- 33
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.